Ilkhom T. Murkamilov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ilkhom T. Murkamilov has a total of 352 co-authors. Here are the top co-authors by number of shared publications:
- Viktor Viktorovich Fomin
Russian Medical Academy of Continuous Professional Education
99 shared publications - Furkat Abdulakhatovich Yusupov
Osh State University
95 shared publications - Kubanich Avenovich Aitbaev
Kyrgyz State Medical Academy named after I.K. Akhunbaev
92 shared publications - Zh. A. Murkamilova
Family Medicine Center № 7
65 shared publications - T. F. Yusupova
Osh State University
49 shared publications - Indira O. Kudaibergenova
Kyrgyz State Medical Academy named after I.K. Akhunbaev
34 shared publications
Latest Publications
- 13 November 2026
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 104 (8)
Circular RNAs in the genomics and pathophysiology of cardiovascular diseases
Cardiovascular diseases (CVDs) remain the leading cause of global mortality, accounting for approximately one-third of all deaths. The growing prevalence of CVDs underscores the urgent need for novel diagnostic and therapeutic approaches. Circular RNAs (circRNAs), a class of single-stranded RNA molecules formed through back-splicing, have attracted considerable attention as potential biomarkers and therapeutic targets due to their unique characteristics. Unlike linear RNAs, circRNAs lack free 3′ and 5′ ends, making them highly resistant to exonuclease degradation and thereby markedly more stable, with a half-life approximately 2–5 times longer than that of linear RNAs. Their stability, tissue- and disease-specific expression patterns, evolutionary conservation, and responsiveness to pathological stimuli enable them to regulate key biological processes such as apoptosis, metabolism, and inflammation. Growing evidence suggests that circRNAs play a role in the pathogenesis of CVDs: circRNA expression levels differ between cardiac tissues of healthy individuals and those of patients with various CVDs; in arterial hypertension, circRNAs 0037909 and 0037911 are closely associated with elevated blood pressure; following myocardial infarction, circRNA FoxO3 exacerbates myocardial injury, whereas circ-Amotl1 attenuates apoptosis and reduces adverse remodeling; in myocardial hypertrophy, knockdown of circSlc8a1 decreases hypertrophy, while circRNA 000203 promotes it by modulating hypertrophic gene expression; in heart failure, an inverse correlation between MICRA levels and left ventricular ejection fraction has been identified, making MICRA a valuable early indicator of left ventricular dysfunction. This review provides a detailed analysis of circRNAs in CVDs, including their biogenesis, molecular mechanisms, and functional roles. It also evaluates their potential as diagnostic and prognostic biomarkers, and discusses therapeutic advances based on circRNAs (synthetic circRNA sponges) and low-molecular-weight drugs. However, despite these promising findings, numerous challenges remain unresolved, including tissue-specific delivery of circRNAs and control of their complex pleiotropic effects. Furthermore, most data on the role of circRNAs, particularly in CVDs, have been obtained from preclinical studies, often involving animal models or in vitro systems. Therefore, further validation through comprehensive preclinical research and well-designed clinical trials is essential. Successful future integration of circRNA-based tools into clinical practice could fundamentally transform CVD management, enabling earlier detection and more personalized treatment strategies.
- 13 November 2026
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 104 (8)
Circular RNAs in the genomics and pathophysiology of cardiovascular diseases
Cardiovascular diseases (CVDs) remain the leading cause of global mortality, accounting for approximately one-third of all deaths. The growing prevalence of CVDs underscores the urgent need for novel diagnostic and therapeutic approaches. Circular RNAs (circRNAs), a class of single-stranded RNA molecules formed through back-splicing, have attracted considerable attention as potential biomarkers and therapeutic targets due to their unique characteristics. Unlike linear RNAs, circRNAs lack free 3′ and 5′ ends, making them highly resistant to exonuclease degradation and thereby markedly more stable, with a half-life approximately 2–5 times longer than that of linear RNAs. Their stability, tissue- and disease-specific expression patterns, evolutionary conservation, and responsiveness to pathological stimuli enable them to regulate key biological processes such as apoptosis, metabolism, and inflammation. Growing evidence suggests that circRNAs play a role in the pathogenesis of CVDs: circRNA expression levels differ between cardiac tissues of healthy individuals and those of patients with various CVDs; in arterial hypertension, circRNAs 0037909 and 0037911 are closely associated with elevated blood pressure; following myocardial infarction, circRNA FoxO3 exacerbates myocardial injury, whereas circ-Amotl1 attenuates apoptosis and reduces adverse remodeling; in myocardial hypertrophy, knockdown of circSlc8a1 decreases hypertrophy, while circRNA 000203 promotes it by modulating hypertrophic gene expression; in heart failure, an inverse correlation between MICRA levels and left ventricular ejection fraction has been identified, making MICRA a valuable early indicator of left ventricular dysfunction. This review provides a detailed analysis of circRNAs in CVDs, including their biogenesis, molecular mechanisms, and functional roles. It also evaluates their potential as diagnostic and prognostic biomarkers, and discusses therapeutic advances based on circRNAs (synthetic circRNA sponges) and low-molecular-weight drugs. However, despite these promising findings, numerous challenges remain unresolved, including tissue-specific delivery of circRNAs and control of their complex pleiotropic effects. Furthermore, most data on the role of circRNAs, particularly in CVDs, have been obtained from preclinical studies, often involving animal models or in vitro systems. Therefore, further validation through comprehensive preclinical research and well-designed clinical trials is essential. Successful future integration of circRNA-based tools into clinical practice could fundamentally transform CVD management, enabling earlier detection and more personalized treatment strategies.
- 9 November 2026
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 29 (10)
Cardiac remodeling in chronic kidney disease associated with overweight and obesity
Chronic kidney disease (CKD) is among the most prevalent non-communicable diseases globally and is recognized as a significant independent risk factor for cardiovascular complications (CVCs). The co-occurrence of overweight or obesity in patients with CKD exacerbates its role as a risk factor for CVCs. Objective. To evaluate the characteristics of left ventricular myocardial remodeling in chronic kidney disease patients with comorbid overweight or obesity, thereby assessing their potential role as a risk factor for cardiovascular complications. Materials and methods. A total of 485 patients with CKD (291 males and 194 females, with a mean age of 43.8 years) were examined. Patients were divided into two groups: CKD with overweight (n=298) and CKD with obesity (n=187). All participants underwent clinical assessments, laboratory tests, and echocardiographic examinations. Results. Patients in the CKD with overweight group exhibited lower hematocrit, red blood cell count, and glomerular filtration rate (GFR), as well as elevated potassium and creatinine levels, compared with those in the CKD with obesity group. Notably, C-reactive protein and glucose levels were markedly higher in the obesity group, whereas 24-hour proteinuria was more significant among overweight patients. Furthermore, the obese cohort had increased levels of total cholesterol and triglycerides. Echocardiographic evaluations revealed that left ventricular (LV) linear dimensions, myocardial mass, and left ventricular mass index (LVMI) were statistically significantly greater in the CKD with obesity group. Concentric LV remodeling was observed in 7.4% of patients with overweight and 5.9% of those with obesity. LV hypertrophy was identified in 51.7% of cases (47.3% in the CKD with overweight group and 58.8% in the CKD with obesity group). Eccentric LV hypertrophy was significantly more prevalent in both patient groups. Concentric hypertrophy was primarily observed in males in the CKD with obesity group, while eccentric hypertrophy was more common among females. A correlation was established between LVMI and the estimated GFR (r = –0.397). Conclusions. In patients with chronic kidney disease who are also classified as overweight, cardiac remodeling predominantly manifests as eccentric left ventricular hypertrophy. As body mass index increases, the incidence of concentric left ventricular hypertrophy also rises, particularly in male patients.
- 9 November 2026
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 29 (10)
Cardiac remodeling in chronic kidney disease associated with overweight and obesity
Chronic kidney disease (CKD) is among the most prevalent non-communicable diseases globally and is recognized as a significant independent risk factor for cardiovascular complications (CVCs). The co-occurrence of overweight or obesity in patients with CKD exacerbates its role as a risk factor for CVCs. Objective. To evaluate the characteristics of left ventricular myocardial remodeling in chronic kidney disease patients with comorbid overweight or obesity, thereby assessing their potential role as a risk factor for cardiovascular complications. Materials and methods. A total of 485 patients with CKD (291 males and 194 females, with a mean age of 43.8 years) were examined. Patients were divided into two groups: CKD with overweight (n=298) and CKD with obesity (n=187). All participants underwent clinical assessments, laboratory tests, and echocardiographic examinations. Results. Patients in the CKD with overweight group exhibited lower hematocrit, red blood cell count, and glomerular filtration rate (GFR), as well as elevated potassium and creatinine levels, compared with those in the CKD with obesity group. Notably, C-reactive protein and glucose levels were markedly higher in the obesity group, whereas 24-hour proteinuria was more significant among overweight patients. Furthermore, the obese cohort had increased levels of total cholesterol and triglycerides. Echocardiographic evaluations revealed that left ventricular (LV) linear dimensions, myocardial mass, and left ventricular mass index (LVMI) were statistically significantly greater in the CKD with obesity group. Concentric LV remodeling was observed in 7.4% of patients with overweight and 5.9% of those with obesity. LV hypertrophy was identified in 51.7% of cases (47.3% in the CKD with overweight group and 58.8% in the CKD with obesity group). Eccentric LV hypertrophy was significantly more prevalent in both patient groups. Concentric hypertrophy was primarily observed in males in the CKD with obesity group, while eccentric hypertrophy was more common among females. A correlation was established between LVMI and the estimated GFR (r = –0.397). Conclusions. In patients with chronic kidney disease who are also classified as overweight, cardiac remodeling predominantly manifests as eccentric left ventricular hypertrophy. As body mass index increases, the incidence of concentric left ventricular hypertrophy also rises, particularly in male patients.
- Open Access
- 7 November 2026
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- No. 3,p. 171-177
Polycystic liver and kidney disease in internal medicine practice
This article presents a clinical case of a 58-year-old female patient with hereditary polycystic kidney and liver disease complicated by stage IV chronic kidney disease. The disease followed a progressive course: from the detection of renal cysts during reproductive age to the development of multisystem involvement, including severe renal dysfunction, hepatobiliary disorders, and secondary cardiovascular complications by the time of admission to the “DOC University Clinic.” Laboratory and instrumental investigations revealed extensive cystic transformation of the parenchyma, azotemia, signs of cholestasis, and multifocal atherosclerosis. A comprehensive personalized treatment approach led to stabilization of the patient’s condition, improvement in quality of life, and relief of symptoms. This case highlights the systemic nature of polycystic disease, as well as the importance of early diagnosis and an interdisciplinary approach to management.
- 7 November 2026
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- No. 3,p. 171-177
Open AccessPolycystic liver and kidney disease in internal medicine practice
This article presents a clinical case of a 58-year-old female patient with hereditary polycystic kidney and liver disease complicated by stage IV chronic kidney disease. The disease followed a progressive course: from the detection of renal cysts during reproductive age to the development of multisystem involvement, including severe renal dysfunction, hepatobiliary disorders, and secondary cardiovascular complications by the time of admission to the “DOC University Clinic.” Laboratory and instrumental investigations revealed extensive cystic transformation of the parenchyma, azotemia, signs of cholestasis, and multifocal atherosclerosis. A comprehensive personalized treatment approach led to stabilization of the patient’s condition, improvement in quality of life, and relief of symptoms. This case highlights the systemic nature of polycystic disease, as well as the importance of early diagnosis and an interdisciplinary approach to management.
- Open Access
- 26 September 2026
- Published by Russian Dialysis Society in Nephrology and Dialysis
- Vol. 28 (3) , 343-351
Comorbidity in kidney transplant recipients
The prevalence of chronic kidney disease (CKD) is increasing because of multiple factors, including rising life expectancy. Kidney transplantation is a form of kidney replacement therapy, alongside haemodialysis and peritoneal dialysis, that prolongs and improves the quality of life of patients with end-stage renal disease (ESRD). Compared with patients receiving dialysis, kidney transplant recipients generally have better survival and quality of life. One of the major challenges in kidney transplantation is the considerable heterogeneity of recipient comorbidities, which directly affects patient selection and post-transplant outcomes. A better understanding of the spectrum and impact of comorbid conditions before transplantation may improve candidate evaluation, guide post-transplant monitoring, and help refine prognostic algorithms. Further research is required to develop individualized approaches to assessing the risks associated with age, comorbidities, and other relevant factors, thereby improving kidney transplant outcomes. The review summarizes the available scientific evidence on comorbidities among kidney transplant recipients .
- 26 September 2026
- Published by Russian Dialysis Society in Nephrology and Dialysis
- Vol. 28 (3) , 343-351
Open AccessComorbidity in kidney transplant recipients
The prevalence of chronic kidney disease (CKD) is increasing because of multiple factors, including rising life expectancy. Kidney transplantation is a form of kidney replacement therapy, alongside haemodialysis and peritoneal dialysis, that prolongs and improves the quality of life of patients with end-stage renal disease (ESRD). Compared with patients receiving dialysis, kidney transplant recipients generally have better survival and quality of life. One of the major challenges in kidney transplantation is the considerable heterogeneity of recipient comorbidities, which directly affects patient selection and post-transplant outcomes. A better understanding of the spectrum and impact of comorbid conditions before transplantation may improve candidate evaluation, guide post-transplant monitoring, and help refine prognostic algorithms. Further research is required to develop individualized approaches to assessing the risks associated with age, comorbidities, and other relevant factors, thereby improving kidney transplant outcomes. The review summarizes the available scientific evidence on comorbidities among kidney transplant recipients .
- 25 September 2026
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 30 (3) , 33-42
Systemic inflammation indices in chronic kidney disease: clinical significance and prognostic aspects
THE AIM: to investigate systemic inflammation indices and their association with risk factors for cardiovascular complications in patients with chronic kidney disease (CKD). PATIENTS AND METHODS. The study included 744 patients (454 men and 290 women) with CKD at predialysis stages; the mean age was 38.3 ± 13.0 years. Patients were divided into two groups: Group 1 – CKD with subnephrotic proteinuria (3.5 g/day, n = 266). All patients underwent peripheral blood and biochemical analyses with the calculation of systemic inflammation indices. RESULTS. In the group of patients with CKD and nephrotic proteinuria, leukocyte count, erythrocyte sedimentation rate, and plasma fibrinogen concentration were significantly higher than in patients with CKD and subnephrotic proteinuria. The platelet-to-lymphocyte ratio (PLR) was higher in patients with CKD and nephrotic proteinuria (8.92 ± 3.39 vs 8.12 ± 2.20, p = 0.001), whereas the lymphocyte-to-C-reactive protein ratio (L/C-RP) was higher in patients with CKD and subnephrotic proteinuria (0.833 [0.167; 2.583] vs 0.323 [0.156; 1.917], p = 0.031). Correlation analysis showed that leukocyte count was positively associated with heart rate (r = 0.264; p < 0.05), total cholesterol (r = 0.119; p < 0.05), and daily proteinuria (r = 0.097; p < 0.05); lymphocyte count correlated with diastolic blood pressure (r = 0.214; p < 0.05); PLR correlated with heart rate (r = 0.376; p < 0.05) and LDL cholesterol (r = 0.374; p < 0.05); LDL cholesterol correlated negatively with L/M (r = –0.253; p < 0.05) and M/L (r = 0.287; p < 0.05). Estimated glomerular filtration rate (eGFR) correlated with L/C-RP (r = 0.300; p < 0.05), systemic inflammation response index (SIRI, r = –0.079; p < 0.05), and neutrophil-to-lymphocyte ratio (NLR, r = –0.077; p < 0.05). A negatively correlation was found between L/C-RP and plasma fibrinogen levels (r = –0.267; p < 0.05). CONCLUSION. In patients with CKD and subnephrotic proteinuria, the lymphocyte-to-C-reactive protein ratio was higher, whereas the platelet-to-lymphocyte ratio was higher in those with CKD and nephrotic proteinuria. Systemic inflammation indices (L/CRP, SIRI, NLR) showed a strong correlation with glomerular filtration rate and were independently associated with the risk of renal function decline and cardiovascular complications.
- 25 September 2026
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 30 (3) , 33-42
Systemic inflammation indices in chronic kidney disease: clinical significance and prognostic aspects
THE AIM: to investigate systemic inflammation indices and their association with risk factors for cardiovascular complications in patients with chronic kidney disease (CKD). PATIENTS AND METHODS. The study included 744 patients (454 men and 290 women) with CKD at predialysis stages; the mean age was 38.3 ± 13.0 years. Patients were divided into two groups: Group 1 – CKD with subnephrotic proteinuria (3.5 g/day, n = 266). All patients underwent peripheral blood and biochemical analyses with the calculation of systemic inflammation indices. RESULTS. In the group of patients with CKD and nephrotic proteinuria, leukocyte count, erythrocyte sedimentation rate, and plasma fibrinogen concentration were significantly higher than in patients with CKD and subnephrotic proteinuria. The platelet-to-lymphocyte ratio (PLR) was higher in patients with CKD and nephrotic proteinuria (8.92 ± 3.39 vs 8.12 ± 2.20, p = 0.001), whereas the lymphocyte-to-C-reactive protein ratio (L/C-RP) was higher in patients with CKD and subnephrotic proteinuria (0.833 [0.167; 2.583] vs 0.323 [0.156; 1.917], p = 0.031). Correlation analysis showed that leukocyte count was positively associated with heart rate (r = 0.264; p < 0.05), total cholesterol (r = 0.119; p < 0.05), and daily proteinuria (r = 0.097; p < 0.05); lymphocyte count correlated with diastolic blood pressure (r = 0.214; p < 0.05); PLR correlated with heart rate (r = 0.376; p < 0.05) and LDL cholesterol (r = 0.374; p < 0.05); LDL cholesterol correlated negatively with L/M (r = –0.253; p < 0.05) and M/L (r = 0.287; p < 0.05). Estimated glomerular filtration rate (eGFR) correlated with L/C-RP (r = 0.300; p < 0.05), systemic inflammation response index (SIRI, r = –0.079; p < 0.05), and neutrophil-to-lymphocyte ratio (NLR, r = –0.077; p < 0.05). A negatively correlation was found between L/C-RP and plasma fibrinogen levels (r = –0.267; p < 0.05). CONCLUSION. In patients with CKD and subnephrotic proteinuria, the lymphocyte-to-C-reactive protein ratio was higher, whereas the platelet-to-lymphocyte ratio was higher in those with CKD and nephrotic proteinuria. Systemic inflammation indices (L/CRP, SIRI, NLR) showed a strong correlation with glomerular filtration rate and were independently associated with the risk of renal function decline and cardiovascular complications.
- 4 September 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (8)
Remodeling of the major arteries of the brain and serum cystatin C levels in patients with non-communicable diseases
Objective. To evaluate serum cystatin C concentrations and the remodeling of major arteries in patients with non-communicable diseases (NCDs). Material and methods. A total of 460 patients diagnosed with NCDs participated in the study, including 229 (49.8%) males and 231 (50.2%) females, with a mean age of 53.4±14.2 years. The subjects were categorized into three groups (1—3) based on serum cystatin C levels. Multiple laboratory, clinical, and instrumental parameters were assessed. Results. In individuals with NCDs, an increase in serum cystatin C from 1 mg/L to 3 mg/L correlated with an elevation in systolic blood pressure from 128±17 mmHg to 145±24 mmHg, and diastolic blood pressure from 84±10 mmHg to 87±12 mmHg. Additionally, total cholesterol levels rose from 4.68±1.00 mmol/L to 5.24±1.91 mmol/L, low-density lipoproteins increased from 3.15±0.88 mmol/L to 3.31±1.56 mmol/L, and triglycerides increased from 1.13 [0.89; 1.61] mmol/L to 1.59 [1.10; 2.45] mmol/L. Potassium levels increased from 4.35±0.61 mmol/L to 4.81±0.96 mmol/L, and creatinine levels rose from 67.3±13.1 μmol/L to 149.4 [102.8; 291.7] μmol/L. C-reactive protein levels rose from 7.8% to 22.8%, and fibrinogen levels increased from 3.0 [2.6; 3.7] g/L to 4.4 [3.3; 5.7] g/L, while urinary protein excretion increased from 423 [0; 100] mg/L to 6722 [0; 1250] mg/L. The estimated glomerular filtration rate decreased from 101.1±15.9 mL/min/1.73 m2 to 44.0 [22.0; 61.0] mL/min/1.73 m2. The diameter of the ascending aorta also increased, from 2.96±0.36 cm to 3.22±0.31 cm, while the prevalence of aortic atherosclerosis rose from 50.0% to 81.3%. The thickness of the intima-media complex (IMC) of the common carotid artery (CCA) increased from 0.87±0.24 mm to 1.04±0.26 mm, and the diameter of the vertebral arteries expanded from 3.47±0.37 mm to 3.62±0.40 mm. A decline in high-density lipoproteins was observed, from 1.16±0.30 mmol/L to 1.09±0.31 mmol/L, and calcium levels decreased from 2.16±0.33 mmol/L to 2.01±0.37 mmol/L. In groups 2 and 3, localized thickening of the CCA IMC of 1.11—1.3 mm was identified in 39 (19.3%) and 22 (18.6%) subjects, respectively. Local thickening of CCA IMC exceeding 1.3 mm was identified in 35 (17.3%) and 21 (17.8%) patients in groups 2 and 3, respectively. Serum cystatin C levels were significantly correlated with the diameter of the ascending aorta (r=0.307; p<0.05), the diameter of the vertebral arteries (r=0.224; p<0.05), and the thickness of the CCA IMC (r=0.324; p<0.05). Conclusion. Measurement of serum cystatin C in patients with non-communicable diseases demonstrates promising diagnostic utility as a laboratory marker of arterial remodeling and reflects the cerebrovascular risk, correlating with the wall thickness of the major arteries of the brain.
- 4 September 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (8)
Remodeling of the major arteries of the brain and serum cystatin C levels in patients with non-communicable diseases
Objective. To evaluate serum cystatin C concentrations and the remodeling of major arteries in patients with non-communicable diseases (NCDs). Material and methods. A total of 460 patients diagnosed with NCDs participated in the study, including 229 (49.8%) males and 231 (50.2%) females, with a mean age of 53.4±14.2 years. The subjects were categorized into three groups (1—3) based on serum cystatin C levels. Multiple laboratory, clinical, and instrumental parameters were assessed. Results. In individuals with NCDs, an increase in serum cystatin C from 1 mg/L to 3 mg/L correlated with an elevation in systolic blood pressure from 128±17 mmHg to 145±24 mmHg, and diastolic blood pressure from 84±10 mmHg to 87±12 mmHg. Additionally, total cholesterol levels rose from 4.68±1.00 mmol/L to 5.24±1.91 mmol/L, low-density lipoproteins increased from 3.15±0.88 mmol/L to 3.31±1.56 mmol/L, and triglycerides increased from 1.13 [0.89; 1.61] mmol/L to 1.59 [1.10; 2.45] mmol/L. Potassium levels increased from 4.35±0.61 mmol/L to 4.81±0.96 mmol/L, and creatinine levels rose from 67.3±13.1 μmol/L to 149.4 [102.8; 291.7] μmol/L. C-reactive protein levels rose from 7.8% to 22.8%, and fibrinogen levels increased from 3.0 [2.6; 3.7] g/L to 4.4 [3.3; 5.7] g/L, while urinary protein excretion increased from 423 [0; 100] mg/L to 6722 [0; 1250] mg/L. The estimated glomerular filtration rate decreased from 101.1±15.9 mL/min/1.73 m2 to 44.0 [22.0; 61.0] mL/min/1.73 m2. The diameter of the ascending aorta also increased, from 2.96±0.36 cm to 3.22±0.31 cm, while the prevalence of aortic atherosclerosis rose from 50.0% to 81.3%. The thickness of the intima-media complex (IMC) of the common carotid artery (CCA) increased from 0.87±0.24 mm to 1.04±0.26 mm, and the diameter of the vertebral arteries expanded from 3.47±0.37 mm to 3.62±0.40 mm. A decline in high-density lipoproteins was observed, from 1.16±0.30 mmol/L to 1.09±0.31 mmol/L, and calcium levels decreased from 2.16±0.33 mmol/L to 2.01±0.37 mmol/L. In groups 2 and 3, localized thickening of the CCA IMC of 1.11—1.3 mm was identified in 39 (19.3%) and 22 (18.6%) subjects, respectively. Local thickening of CCA IMC exceeding 1.3 mm was identified in 35 (17.3%) and 21 (17.8%) patients in groups 2 and 3, respectively. Serum cystatin C levels were significantly correlated with the diameter of the ascending aorta (r=0.307; p<0.05), the diameter of the vertebral arteries (r=0.224; p<0.05), and the thickness of the CCA IMC (r=0.324; p<0.05). Conclusion. Measurement of serum cystatin C in patients with non-communicable diseases demonstrates promising diagnostic utility as a laboratory marker of arterial remodeling and reflects the cerebrovascular risk, correlating with the wall thickness of the major arteries of the brain.
- 28 August 2026
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 104 (6) , 439-451
Hyperuricemia and the cardio-reno-metabolic continuum in chronic kidney disease
Objective. To investigate the relationship between serum uric acid levels and echocardiographic (EchoCG) parameters, and to assess the association of hyperuricemia with cardiovascular and renal abnormalities in patients with chronic kidney disease (CKD). Material and methods. A cross-sectional retrospective study included clinical, instrumental, laboratory, and EchoCG data from 473 patients (307 men and 166 women) with a confi rmed diagnosis of CKD. The mean age of the study participants was 38.5 ± 12.7 years. Hyperuricemia was defi ned as serum uric acid ≥ 0.42 mmol/L in men and ≥ 0.36 mmol/L in women. Patients were divided into subgroups: CKD with hyperuricemia (n = 199) and CKD without hyperuricemia (n = 274). Results. Among all patients with CKD (n = 473), hyperuricemia was observed in 199 cases (42.0%). Compared with patients without hyperuricemia, those with CKD and hyperuricemia had signifi cantly higher mean age, body mass index, systolic and diastolic blood pressure the size of cardiac structures according to ECHOCG data and serum creatinine levels were statistically significantly higher. In contrast, hemoglobin concentration, red blood cell count, and estimated glomerular fi ltration rate (eGFR) were significantly lower. Signifi cant correlations of serum uric acid were found with systolic and diastolic blood pressure, eGFR, left atrial anteroposterior diameter, left ventricular end-systolic and end-diastolic diameter, interventricular septum thickness, posterior wall thickness of the left ventricle, left ventricular ejection fraction, and venous blood glucose. Conclusion. The study demonstrated a signifi cant contribution of hyperuricemia to alterations in the geometry of the left heart chambers and a decline in renal filtration function.
- 28 August 2026
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 104 (6) , 439-451
Hyperuricemia and the cardio-reno-metabolic continuum in chronic kidney disease
Objective. To investigate the relationship between serum uric acid levels and echocardiographic (EchoCG) parameters, and to assess the association of hyperuricemia with cardiovascular and renal abnormalities in patients with chronic kidney disease (CKD). Material and methods. A cross-sectional retrospective study included clinical, instrumental, laboratory, and EchoCG data from 473 patients (307 men and 166 women) with a confi rmed diagnosis of CKD. The mean age of the study participants was 38.5 ± 12.7 years. Hyperuricemia was defi ned as serum uric acid ≥ 0.42 mmol/L in men and ≥ 0.36 mmol/L in women. Patients were divided into subgroups: CKD with hyperuricemia (n = 199) and CKD without hyperuricemia (n = 274). Results. Among all patients with CKD (n = 473), hyperuricemia was observed in 199 cases (42.0%). Compared with patients without hyperuricemia, those with CKD and hyperuricemia had signifi cantly higher mean age, body mass index, systolic and diastolic blood pressure the size of cardiac structures according to ECHOCG data and serum creatinine levels were statistically significantly higher. In contrast, hemoglobin concentration, red blood cell count, and estimated glomerular fi ltration rate (eGFR) were significantly lower. Signifi cant correlations of serum uric acid were found with systolic and diastolic blood pressure, eGFR, left atrial anteroposterior diameter, left ventricular end-systolic and end-diastolic diameter, interventricular septum thickness, posterior wall thickness of the left ventricle, left ventricular ejection fraction, and venous blood glucose. Conclusion. The study demonstrated a signifi cant contribution of hyperuricemia to alterations in the geometry of the left heart chambers and a decline in renal filtration function.
- 26 July 2026
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 30 (2) , 66-75
Cardiac and aortic lesions in nephrotic syndrome
THE AIM: To study heart and aortic involvement in patients with nephrotic syndrome (NS) depending on sex. PATIENTS AND METHODS. A retrospective analysis included 170 patients (mean age 32.1±12.0 years) with verified NS based on clinical and laboratory findings. All participants were divided into two subgroups: men (n=105) and women (n=65). Laboratory parameters, general clinical data, electrocardiographic (ECG), and echocardiographic parameters were assessed. RESULTS . In men with NS, the mean levels of diastolic and mean arterial pressure, platelet count, total cholesterol (TC), and creatinine were significantly higher, while total protein concentration was significantly lower compared to women. Women with NS had a statistically significantly higher heart rate, while hemoglobin (Hb), hematocrit, erythrocyte count, and mean corpuscular hemoglobin levels were significantly lower. Among all patients with NS, ECG signs of myocardial excitability and conduction disturbances were detected in 17.6 % and 4.1 % of cases, respectively. Left ventricular (LV) repolarization abnormalities were observed in 20 patients (11.7 %). Pathological ECG changes were found in 29 (27.6 %) men and 28 (43.0 %) women. Men had significantly larger linear dimensions of the LV, right ventricle, and aortic outflow tract compared to women. LV myocardial hypertrophy was detected in 17 (10 %) patients, while concentric LV remodeling was observed in 5 (2.9 %) cases. LV myocardial hypertrophy was more common in women. In men with NS, the LV myocardial mass index was significantly correlated with daily proteinuria (r=0.378; p=0.036), TC level (r=0.222; p=0.041), and fibrinogen concentration (r=0.306; p=0.021), while it was inversely correlated with albumin concentration (r=0.371; p=0.039). In women, the LV myocardial mass index showed a positive correlation with daily proteinuria (r=0.265; p=0.016) and fibrinogen concentration (r=0.230; p=0.019). CONCLUSION. Patients with NS frequently exhibit ECG signs of myocardial excitability and LV repolarization disturbances. Cardiac involvement in NS is primarily represented by concentric LV remodeling in men and eccentric LV myocardial hypertrophy in women. Regardless of sex, LV myocardial mass is strongly associated with daily proteinuria and fibrinogen concentration, while the diameter of the aortic outflow tract is linked to diastolic blood pressure levels.
- 26 July 2026
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 30 (2) , 66-75
Cardiac and aortic lesions in nephrotic syndrome
THE AIM: To study heart and aortic involvement in patients with nephrotic syndrome (NS) depending on sex. PATIENTS AND METHODS. A retrospective analysis included 170 patients (mean age 32.1±12.0 years) with verified NS based on clinical and laboratory findings. All participants were divided into two subgroups: men (n=105) and women (n=65). Laboratory parameters, general clinical data, electrocardiographic (ECG), and echocardiographic parameters were assessed. RESULTS . In men with NS, the mean levels of diastolic and mean arterial pressure, platelet count, total cholesterol (TC), and creatinine were significantly higher, while total protein concentration was significantly lower compared to women. Women with NS had a statistically significantly higher heart rate, while hemoglobin (Hb), hematocrit, erythrocyte count, and mean corpuscular hemoglobin levels were significantly lower. Among all patients with NS, ECG signs of myocardial excitability and conduction disturbances were detected in 17.6 % and 4.1 % of cases, respectively. Left ventricular (LV) repolarization abnormalities were observed in 20 patients (11.7 %). Pathological ECG changes were found in 29 (27.6 %) men and 28 (43.0 %) women. Men had significantly larger linear dimensions of the LV, right ventricle, and aortic outflow tract compared to women. LV myocardial hypertrophy was detected in 17 (10 %) patients, while concentric LV remodeling was observed in 5 (2.9 %) cases. LV myocardial hypertrophy was more common in women. In men with NS, the LV myocardial mass index was significantly correlated with daily proteinuria (r=0.378; p=0.036), TC level (r=0.222; p=0.041), and fibrinogen concentration (r=0.306; p=0.021), while it was inversely correlated with albumin concentration (r=0.371; p=0.039). In women, the LV myocardial mass index showed a positive correlation with daily proteinuria (r=0.265; p=0.016) and fibrinogen concentration (r=0.230; p=0.019). CONCLUSION. Patients with NS frequently exhibit ECG signs of myocardial excitability and LV repolarization disturbances. Cardiac involvement in NS is primarily represented by concentric LV remodeling in men and eccentric LV myocardial hypertrophy in women. Regardless of sex, LV myocardial mass is strongly associated with daily proteinuria and fibrinogen concentration, while the diameter of the aortic outflow tract is linked to diastolic blood pressure levels.
- 8 July 2026
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 29 (6)
Iron deficiency in patients with the chronic kidney disease: frequency and clinical-prognostic aspects
In recent years, a significant global rise in the prevalence of chronic kidney disease (CKD) and its associated cardiovascular complications (CVC) has been observed. The urgent need to slow the advancement of renal impairment and minimize the risk of cardiovascular complications (CVC) is critical, particularly in the context of managing metabolic disorders like iron deficiency (ID). Objective. Tho evaluate the prevalence of iron deficiency and its association with various risk factors contributing to the progression of renal dysfunction in individuals diagnosed with CKD. Materials and methods. This study included 1.309 patients with CKD, comprising 731 males and 578 females aged 16—78 years, with a mean age of 40.5±13.6 years. Comprehensive clinical and laboratory evaluations were conducted, including an assessment of the frequency of iron deficiency categorized by CKD stage and sex. Statistical analyses were performed utilizing Statistica 10.0 and Microsoft Excel. Results. Among the cohort, patients with a glomerular filtration rate (GFR) of ≥60 mL/min (Group 1) exhibited higher incidences of grade I obesity, elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and daily proteinuria, as well as decreased serum total protein levels. Conversely, patients with a GFR of <60 mL/min (Group 2) displayed older age, increased hemodynamic indices, higher erythrocyte sedimentation rate, elevated glucose and potassium levels, and reduced high-density lipoprotein cholesterol (HDL-C) and calcium concentrations. Serum iron levels were significantly different, measuring 17.0±7.1 µmol/L in Group 1 compared to 14.8±7.8 µmol/L in Group 2 (p<0.001). The prevalence of iron deficiency increased with the progression of CKD, from 8.7% at stage C1 to 28.7% at stage C5. Gender differences in iron deficiency prevalence were particularly pronounced at stages C3A (7.5% in males vs. 21.1% in females) and C5 (26.3% in males vs. 31.4% in females). Overall, iron deficiency was identified in 246 patients (26.8%): 116 males (15.8%) and 130 females (22.4%). Conclusion. The findings indicate that serum iron concentration decreases with the deterioration of renal filtration function in patients with CKD, particularly among females. The prevalence of iron deficiency increases with disease progression, peaking at the pre-dialysis stage. Furthermore, iron deficiency in CKD is closely associated with modifiable cardiovascular risk factors.
- 8 July 2026
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 29 (6)
Iron deficiency in patients with the chronic kidney disease: frequency and clinical-prognostic aspects
In recent years, a significant global rise in the prevalence of chronic kidney disease (CKD) and its associated cardiovascular complications (CVC) has been observed. The urgent need to slow the advancement of renal impairment and minimize the risk of cardiovascular complications (CVC) is critical, particularly in the context of managing metabolic disorders like iron deficiency (ID). Objective. Tho evaluate the prevalence of iron deficiency and its association with various risk factors contributing to the progression of renal dysfunction in individuals diagnosed with CKD. Materials and methods. This study included 1.309 patients with CKD, comprising 731 males and 578 females aged 16—78 years, with a mean age of 40.5±13.6 years. Comprehensive clinical and laboratory evaluations were conducted, including an assessment of the frequency of iron deficiency categorized by CKD stage and sex. Statistical analyses were performed utilizing Statistica 10.0 and Microsoft Excel. Results. Among the cohort, patients with a glomerular filtration rate (GFR) of ≥60 mL/min (Group 1) exhibited higher incidences of grade I obesity, elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and daily proteinuria, as well as decreased serum total protein levels. Conversely, patients with a GFR of <60 mL/min (Group 2) displayed older age, increased hemodynamic indices, higher erythrocyte sedimentation rate, elevated glucose and potassium levels, and reduced high-density lipoprotein cholesterol (HDL-C) and calcium concentrations. Serum iron levels were significantly different, measuring 17.0±7.1 µmol/L in Group 1 compared to 14.8±7.8 µmol/L in Group 2 (p<0.001). The prevalence of iron deficiency increased with the progression of CKD, from 8.7% at stage C1 to 28.7% at stage C5. Gender differences in iron deficiency prevalence were particularly pronounced at stages C3A (7.5% in males vs. 21.1% in females) and C5 (26.3% in males vs. 31.4% in females). Overall, iron deficiency was identified in 246 patients (26.8%): 116 males (15.8%) and 130 females (22.4%). Conclusion. The findings indicate that serum iron concentration decreases with the deterioration of renal filtration function in patients with CKD, particularly among females. The prevalence of iron deficiency increases with disease progression, peaking at the pre-dialysis stage. Furthermore, iron deficiency in CKD is closely associated with modifiable cardiovascular risk factors.
- 24 April 2026
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 66 (3) , 36-46
Left Ventricular Hypertrophy in Chronic Kidney Disease: Prevalence and Association With Renal Function Parameters
Aim To evaluate the prevalence of left ventricular hypertrophy (LVH) and its relationship with renal function parameters in patients with chronic kidney disease (CKD). Material and methods This cross-sectional retrospective cohort study included 1,080 patients with pre-dialysis CKD. The mean age was 39.0±12.9 years (17-74 years; median, 38 [28-49 years]). Patients were divided into three groups: Group 1 (n=381; GFR ≥60 mL/min/1.73 m²), Group 2 (n=181; GFR 59-30 mL/min/1.73 m²), and Group 3 (n=518; GFR ≤29 mL/min/1.73 m²). All patients underwent clinical and laboratory evaluation and echocardiography. Statistical analysis was performed using STATISTICA 10.0, utilizing Student's t -test, Mann-Whitney U test, ANOVA, and Spearman's correlation. Differences were considered statistically significant at p Results The LV linear dimensions and mass index were significantly greater in patients with more pronounced renal impairment. Signs of LVH were identified in 489 patients (45.2%). The prevalence of LVH increased alongside the progression of CKD, reaching 8.8%, 26.5%, 35.5%, 35.1%, 52.7%, and 76.4% in stages C1-C5, respectively. Eccentric LVH was more prevalent than concentric LVH. LV mass index and relative wall thickness correlated significantly with both GFR and proteinuria levels. Conclusion Patients with CKD exhibit a high prevalence of LVH, which rises as the GFR declines and peaks at the advanced stages of the disease. LVH is predominantly eccentric. There is a statistically significant relationship between LV remodeling parameters and renal function, specifically GFR and proteinuria.
- 24 April 2026
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 66 (3) , 36-46
Left Ventricular Hypertrophy in Chronic Kidney Disease: Prevalence and Association With Renal Function Parameters
Aim To evaluate the prevalence of left ventricular hypertrophy (LVH) and its relationship with renal function parameters in patients with chronic kidney disease (CKD). Material and methods This cross-sectional retrospective cohort study included 1,080 patients with pre-dialysis CKD. The mean age was 39.0±12.9 years (17-74 years; median, 38 [28-49 years]). Patients were divided into three groups: Group 1 (n=381; GFR ≥60 mL/min/1.73 m²), Group 2 (n=181; GFR 59-30 mL/min/1.73 m²), and Group 3 (n=518; GFR ≤29 mL/min/1.73 m²). All patients underwent clinical and laboratory evaluation and echocardiography. Statistical analysis was performed using STATISTICA 10.0, utilizing Student's t -test, Mann-Whitney U test, ANOVA, and Spearman's correlation. Differences were considered statistically significant at p Results The LV linear dimensions and mass index were significantly greater in patients with more pronounced renal impairment. Signs of LVH were identified in 489 patients (45.2%). The prevalence of LVH increased alongside the progression of CKD, reaching 8.8%, 26.5%, 35.5%, 35.1%, 52.7%, and 76.4% in stages C1-C5, respectively. Eccentric LVH was more prevalent than concentric LVH. LV mass index and relative wall thickness correlated significantly with both GFR and proteinuria levels. Conclusion Patients with CKD exhibit a high prevalence of LVH, which rises as the GFR declines and peaks at the advanced stages of the disease. LVH is predominantly eccentric. There is a statistically significant relationship between LV remodeling parameters and renal function, specifically GFR and proteinuria.